{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:18:35Z","timestamp":1749010715468,"version":"3.41.0"},"reference-count":32,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold>Adalimumab effectiveness on clinical, functional and work-related outcomes was evaluated in patients with active ankylosing spondylitis or psoriatic arthritis treated in routine clinical practice in central\u2013eastern Europe.<jats:bold>Methods:<\/jats:bold>Patients (n = 555) were followed for 12 months. Primary end point was percentage of patients with a treatment response (\u226550% decrease from baseline in Bath Ankylosing Spondylitis Disease Activity Index or \u22651.2 point decrease from baseline in Disease Activity Index-28 joint for axial or peripheral symptoms, respectively). Functional status was evaluated by the Bath Ankylosing Spondylitis Functional Index and Health Assessment Questionnaire Disability Index. Working ability was evaluated by the Work Productivity and Activity Impairment Questionnaire \u2212 Specific Health Problem.<jats:bold>Results:<\/jats:bold>76.1% of patients with axial symptoms and 83.5% with peripheral symptoms achieved a treatment response. Frequency of extra-articular manifestations decreased. Improvements were observed in functional status and workability. No new safety signals were observed.<jats:bold>Conclusion:<\/jats:bold>Adalimumab was effective and well tolerated during real-world use in central\u2013eastern Europe.<\/jats:p>","DOI":"10.2217\/cer-2016-0020","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T11:00:16Z","timestamp":1468580416000},"page":"475-485","source":"Crossref","is-referenced-by-count":4,"title":["Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central\u2013eastern Europe"],"prefix":"10.57264","volume":"5","author":[{"given":"S\u00e1ndor","family":"Sz\u00e1nt\u00f3","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyula","family":"Po\u00f3r","sequence":"additional","affiliation":[{"name":"National Institute of Rheumatology &amp; Physiotherapy, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Opris","sequence":"additional","affiliation":[{"name":"\u201cSf. Maria\u201d Clinical Hospital, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg","family":"Iaremenko","sequence":"additional","affiliation":[{"name":"National Medical University, Kyiv, Ukraine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leona","family":"Proch\u00e1zkov\u00e1","sequence":"additional","affiliation":[{"name":"Rheumatology Division, 2nd Department of Internal Medicine, St Anne\u2019s University Hospital Brno, Brno, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reet","family":"Kuuse","sequence":"additional","affiliation":[{"name":"Tartu University Hospital, Tartu, Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Nagy","sequence":"additional","affiliation":[{"name":"AbbVie Ltd, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentyn","family":"Chernyshov","sequence":"additional","affiliation":[{"name":"AbbVie Biopharmaceuticals GmbH, Minsk, Belarus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e1l","family":"G\u00e9her","sequence":"additional","affiliation":[{"name":"Hospitaller Brothers of St John of God Hospital, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.12703\/P6-78","article-title":"Advances in managing ankylosing spondylitis","volume":"6","author":"Daikh DI","year":"2014","unstructured":"Daikh DI , Chen PP . Advances in managing ankylosing spondylitis . F1000Prime Rep. 6 , 78 ( 2014 ).","journal-title":"F1000Prime Rep."},{"issue":"5","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/1759720X15595966","article-title":"Making the next steps in psoriatic arthritis management: current status and future directions","volume":"7","author":"Sritheran D","year":"2015","unstructured":"Sritheran D , Leung YY . Making the next steps in psoriatic arthritis management: current status and future directions . Ther. Adv. Musculoskelet. Dis. 7 ( 5 ), 173 \u2013 186 ( 2015 ).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"7","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde D","year":"2006","unstructured":"van der Heijde D , Kivitz A , Schiff MH Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial . Arthritis Rheum. 54 ( 7 ), 2136 \u2013 2146 ( 2006 ).","journal-title":"Arthritis Rheum."},{"issue":"10","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease PJ","year":"2005","unstructured":"Mease PJ , Gladman DD , Ritchlin CT Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial . Arthritis Rheum. 52 ( 10 ), 3279 \u2013 3289 ( 2005 ).","journal-title":"Arthritis Rheum."},{"issue":"3","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/ar3054","article-title":"Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy","volume":"12","author":"Rudwaleit M","year":"2010","unstructured":"Rudwaleit M , Van den Bosch F , Kron M , Kary S , Kupper H . Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy . Arthritis Res. Ther. 12 ( 3 ), R117 ( 2010 ).","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/1756-185X.12245","article-title":"Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta-analysis","volume":"17","author":"Wang H","year":"2014","unstructured":"Wang H , Zuo D , Sun M , Hua Y , Cai Z . Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta-analysis . Int. J. Rheum. Dis. 17 ( 2 ), 142 \u2013 148 ( 2014 ).","journal-title":"Int. J. Rheum. Dis."},{"issue":"7","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/rheumatology\/keu438","article-title":"Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab","volume":"54","author":"van der Heijde D","year":"2015","unstructured":"van der Heijde D , Breban M , Halter D Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab . Rheumatology (Oxford) 54 ( 7 ), 1210 \u2013 1219 ( 2015 ).","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease PJ","year":"2009","unstructured":"Mease PJ , Ory P , Sharp JT Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) . Ann. Rheum. Dis. 68 ( 5 ), 702 \u2013 709 ( 2009 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden S","year":"1984","unstructured":"van der Linden S , Valkenburg HA , Cats A . Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria . Arthritis Rheum. 27 ( 4 ), 361 \u2013 368 ( 1984 ).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll JM","year":"1973","unstructured":"Moll JM , Wright V . Psoriatic arthritis . Semin. Arthritis Rheum. 3 , 55 \u2013 78 ( 1973 ).","journal-title":"Semin. Arthritis Rheum."},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification Criteria for Psoriatic Arthritis. Development of new criteria from a large international study","volume":"54","author":"Taylor W","year":"2006","unstructured":"Taylor W , Gladman D , Helliwell P Classification Criteria for Psoriatic Arthritis. Development of new criteria from a large international study . Arthritis Rheum. 54 , 2665 \u2013 2673 ( 2006 ).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_4_14_2","unstructured":"Humira . Summary of Product Characteristics . www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000481\/WC500050870.pdf"},{"issue":"1","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas C","year":"2009","unstructured":"Lukas C , Landew\u00e9 R , Sieper J Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis . Ann. Rheum. Dis. 68 ( 1 ), 18 \u2013 24 ( 2009 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde D","year":"2009","unstructured":"van der Heijde D , Lie E , Kvien TK ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis . Ann. Rheum. Dis. 68 ( 12 ), 1811 \u2013 1818 ( 2009 ).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_4_17_2","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity","volume":"21","author":"Garrett S","year":"1994","unstructured":"Garrett S , Jenkinson T , Kennedy LG , Whitelock H , Gaisford P , Calin A . A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity . Index J. Rheumatol. 21 , 2286 \u2013 2291 ( 1994 ).","journal-title":"Index J. Rheumatol."},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo ML","year":"1995","unstructured":"Prevoo ML , van \u2018t Hof MA , Kuper HH , van Leeuwen MA , van de Putte LBA , van Riel PL . Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis . Arthritis Rheum. 38 , 44 \u2013 48 ( 1995 ).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_4_19_2","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin A","year":"1994","unstructured":"Calin A , Garrett S , Whitelock H A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index . J. Rheumatol. 21 , 2281 \u2013 2285 ( 1994 ).","journal-title":"J. Rheumatol."},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries JF","year":"1980","unstructured":"Fries JF , Spitz P , Kraines G , Holman H . Measurement of patient outcome in arthritis . Arthritis Rheum. 23 , 137 \u2013 145 ( 1980 ).","journal-title":"Arthritis Rheum."},{"issue":"5","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment measure","volume":"4","author":"Reilly MC","year":"1993","unstructured":"Reilly MC , Zbrozek AS , Dukes E . The validity and reproducibility of a work productivity and activity impairment measure . Pharmacoeconomics 4 ( 5 ), 353 \u2013 365 ( 1993 ).","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10067-014-2652-9","article-title":"Extra-articular manifestations in psoriatic arthritis patients","volume":"34","author":"Peluso R","year":"2015","unstructured":"Peluso R , Iervolino S , Vitiello M , Bruner V , Lupoli G , Di Minno MN . Extra-articular manifestations in psoriatic arthritis patients . Clin. Rheumatol. 34 ( 4 ), 745 \u2013 753 ( 2015 ).","journal-title":"Clin. Rheumatol."},{"issue":"12","key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1136\/ard.2005.042630","article-title":"An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis","volume":"65","author":"Pham T","year":"2006","unstructured":"Pham T , Landew\u00e9 R , van der Linden S An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis . Ann. Rheum. Dis. 65 ( 12 ), 1620 \u2013 1625 ( 2006 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.60.4.353","article-title":"Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients","volume":"60","author":"Boonen A","year":"2001","unstructured":"Boonen A , Chorus A , Miedema H Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients . Ann. Rheum. Dis. 60 ( 4 ), 353 \u2013 358 ( 2001 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/ard.61.5.429","article-title":"Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries","volume":"61","author":"Boonen A","year":"2002","unstructured":"Boonen A , van der Heijde D , Landew\u00e9 R Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries . Ann. Rheum. Dis. 61 ( 5 ), 429 \u2013 437 ( 2002 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/ard.2008.092049","article-title":"Work disability and health-related quality of life in males and females with psoriatic arthritis","volume":"68","author":"Wallenius M","year":"2009","unstructured":"Wallenius M , Skomsvoll JF , Koldingsnes W Work disability and health-related quality of life in males and females with psoriatic arthritis . Ann. Rheum. Dis. 68 ( 5 ), 685 \u2013 689 ( 2009 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/keq131","article-title":"Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register","volume":"49","author":"Verstappen SM","year":"2010","unstructured":"Verstappen SM , Watson KD , Lunt M Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register . Rheumatology (Oxford) 49 ( 8 ), 1570 \u2013 1577 ( 2010 ).","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3899\/jrheum.090242","article-title":"Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis","volume":"37","author":"Maksymowych WP","year":"2010","unstructured":"Maksymowych WP , Gooch KL , Wong RL , Kupper H , van der Heijde D . Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis . J. Rheumatol. 37 ( 2 ), 385 \u2013 392 ( 2010 ).","journal-title":"J. Rheumatol."},{"issue":"5","key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.berh.2014.10.004","article-title":"Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis","volume":"28","author":"Machado PM","year":"2014","unstructured":"Machado PM , Raychaudhuri SP . Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis . Best Pract. Res. Clin. Rheumatol. 28 ( 5 ), 711 \u2013 728 ( 2014 ).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"4","key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/BOR.0b013e3283470f23","article-title":"How to measure disease activity in axial spondyloarthritis?","volume":"23","author":"Machado P","year":"2011","unstructured":"Machado P , van der Heijde D . How to measure disease activity in axial spondyloarthritis? Curr. Opin. Rheumatol. 23 ( 4 ), 339 \u2013 345 ( 2011 ).","journal-title":"Curr. Opin. Rheumatol."},{"issue":"3","key":"e_1_3_4_31_2","first-page":"126","article-title":"[OP-0166] Performance of the ankylosing spondylitis disease activity score in 1,250 ankylosing spondylitis patients treated with adalimumab","volume":"68","author":"van der Heijde D","year":"2009","unstructured":"van der Heijde D , Landewe R , Rudwaleit M [OP-0166] Performance of the ankylosing spondylitis disease activity score in 1,250 ankylosing spondylitis patients treated with adalimumab . Ann. Rheum. Dis. 68 ( Suppl. 3 ), 126 ( 2009 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper J","year":"2009","unstructured":"Sieper J , Rudwaleit M , Baraliakos X The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis . Ann. Rheum. Dis. 68 ( Suppl. 2 ), ii1 \u2013 ii44 ( 2009 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/ar4452","article-title":"Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a Phase 3b and subsequent postmarketing observational study","volume":"16","author":"Burmester GR","year":"2014","unstructured":"Burmester GR , Matucci-Cerinic M , Mariette X Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a Phase 3b and subsequent postmarketing observational study . Arthritis Res. Ther. 16 ( 1 ), R24 ( 2014 ).","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"410.e6","DOI":"10.1016\/j.jaad.2015.06.038","article-title":"Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis","volume":"73","author":"Menter A","year":"2015","unstructured":"Menter A , Tha\u00e7i D , Papp KA Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis . J. Am. Acad. Dermatol. 73 ( 3 ), 410.e6 \u2013 419.e6 ( 2015 ).","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2016-0020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T01:21:18Z","timestamp":1749000078000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2016-0020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.2217\/cer-2016-0020"],"URL":"https:\/\/doi.org\/10.2217\/cer-2016-0020","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}